r/PeptideGuide

Somewhere around 35 or 40, even people who train hard and eat well hit a wall. Workouts feel flat, recovery drags, and fasting glucose creeps up with nothing changing on the diet side. One proposed piece of that puzzle is MOTS-C, a 16 amino acid peptide discovered in 2015 by a USC group. Your mitochondria make it, its levels rise with exercise, and circulating levels appear to fall with age. This is the full breakdown: how it works, what it does and doesn't do, the human data, side effects, dosing, stacking and reconstitution.

How MOTS-C works

Most peptides are encoded in nuclear DNA. MOTS-C is encoded in the mitochondrial genome, inside the 12S rRNA gene. It doesn't grab AMPK directly. It interferes with the folate cycle, which makes a molecule called AICAR accumulate, and AICAR flips the AMPK switch. AMPK is the cell's fuel gauge, and activating it pushes cells to take up glucose and burn fat.

Under metabolic stress, cell and mouse work shows MOTS-C moving from the mitochondria into the nucleus. There it binds DNA and regulates gene expression, including antioxidant response genes. A peptide born in one genome changing what another genome reads is why people call it dual-genome crosstalk. This is why the community frames it as the software upgrade, while SS-31 is the hardware, working on the physical membrane.

Exercise mimetic, with a catch

Reynolds 2021 (Nature Communications) found that MOTS-C levels rise in human muscle and plasma after exercise, and that treating mice of different ages improved their physical performance. That's where the "exercise mimetic" label comes from.

Here's the catch. I couldn't find a completed human trial of injected MOTS-C for any metabolic or performance use. The human evidence is observational: the body makes more of it when you exercise. Whether an injection reproduces that in people hasn't been tested.

What it does and doesn't do

MOTS-C isn't a fat burner and it doesn't suppress appetite the way GLP-1s do. Any weight change is an indirect effect of how cells handle fuel. Three downstream mechanisms get cited: browning of white fat into calorie-burning beige fat, mitochondrial biogenesis through PGC-1α, and lower myostatin expression, which would protect muscle. All three come mostly from mouse and cell work, and they're thinner than the AMPK evidence.

The mouse data also has a limit. The metabolic benefits show up in animals under stress, like high-fat diets or ovariectomy, with no apparent effect in unchallenged rodents. One line of work saw benefit in male mice but not pre-menopausal females. If you're lean, insulin-sensitive and 25, the mouse data doesn't promise you much.

The liver data

The human liver numbers come from CB4211, a MOTS-C analog, not MOTS-C itself. In a Phase 1b study (CohBar, company-reported), 20 obese adults with fatty liver got 25 mg subcutaneously every day for 4 weeks. ALT fell 21% versus a 4% rise on placebo. AST fell 28% versus an 11% drop on placebo. Liver fat on MRI fell about 5 percentage points in both groups, so the drug didn't separate from placebo there.

So enzymes moved and fat didn't. It's also 20 people, 4 weeks, and a dose roughly 10 to 25 times what the community uses. It's not a fatty liver treatment, and it isn't an answer to what injected MOTS-C does at 1-2 mg.

Side effects and who should skip it

There's no peer-reviewed human safety data for injected MOTS-C. Community reports put severe reactions around 10% of users, including systemic hives, sudden hypoglycemia, palpitations and heart rate spikes. That number comes from user reports, not a trial.

Hypoglycemia is most likely during hard resistance training or when MOTS-C is stacked with metformin, berberine, GLP-1s or insulin. Carry fast carbs.

For injection site reactions or hives, the community workaround is switching from SubQ to IM in the deltoid or glute. The reasoning is that muscle has fewer mast cells than fat. It's plausible, and it's anecdotal.

Skip it entirely if you have a history of severe allergic reactions or MCAS, are a drug-tested athlete (WADA lists it as an AMPK activator), are pregnant or breastfeeding, or have an unmanaged cardiac condition.

Dosing tiers (community-reported)

None of these come from human trials of injected MOTS-C. Tier 1 is a screening dose of 250-500 mcg/day for 2 weeks, SubQ or IM, just to see how you react. Tier 2 is 1-2 mg/day, 5 days on and 2 off, for 8 weeks, which is the usual range for metabolic and exercise goals. Tier 3 is a 2-5 mg/day ceiling on the same 5/2 schedule for 8-12 weeks, for significant insulin resistance or inflammation under close tracking.

The usual cycle is 8 weeks on, 8 weeks off. That's convention, not data. Start low, even if you think you're not the allergic type.

Sequencing with SS-31

The community theory is to fix the base before you build on it. SS-31 binds cardiolipin in the inner mitochondrial membrane and stabilizes it. MOTS-C expands capacity and reprograms fuel use. The reasoning goes that ramping up production on damaged membranes is backwards.

The popular protocol runs SS-31 alone at 1-5 mg/day for weeks 1-4. Then MOTS-C at 1-2 mg/day joins for weeks 5-12, with SS-31 overlapping for 4-8 weeks before tapering. Some people add Humanin as a third phase for neuroprotection and vascular health.

No study tests any of this combination, and SS-31's own human record is mixed. It's approved only for Barth syndrome and missed its endpoints in several larger trials. Treat the sequence as a reasoned hypothesis.

Reconstitution and stability

Add 2 mL of bacteriostatic water to a 10 mg vial and you get 5 mg/mL. A 1 mg dose is 0.2 mL, which is 20 units on a U-100 insulin syringe.

You'll hear that MOTS-C degrades within 15 minutes of reconstitution. That mixes up two things: how fast it clears from your blood and how long it lasts in a vial. A short plasma half-life says nothing about shelf stability. It also doesn't rule out lasting effects, since a peptide that changes gene expression can outlast its time in circulation.

Vendors and users report 30 days of stability refrigerated. I haven't seen a peer-reviewed stability study, so treat that as a working number.

Where it stands legally

MOTS-C isn't approved for human use. FDA staff recommended against adding it to the 503A bulk substances list, and the advisory committee voted 7-5-2 in favor anyway. Rulemaking typically takes 8-18 months, so the status can still change.

What MOTS-C can't do for you

It amplifies habits you already have. It can't replace progressive resistance training, protein, sleep or baseline hormones, and it won't fix a broken foundation. If you use it, start with a screening dose, go slow and cycle it.

TL;DR

• MOTS-C is a mitochondrial-encoded peptide that activates AMPK by raising AICAR and, under stress, moves to the nucleus to regulate genes, mostly shown in cell and mouse work.
• Its levels rise after exercise in humans, but I couldn't find a completed human trial showing that injecting it does the same.
• The fat browning, PGC-1α and myostatin mechanisms are mostly mouse and cell data, and mouse benefits appear mainly in metabolically challenged animals.
• The 21-28% ALT/AST drop comes from CB4211, a MOTS-C analog, in 20 people at 25 mg for 4 weeks, and liver fat on MRI didn't separate from placebo.
• Dosing tiers, the roughly 10% severe reaction figure, the 30-day stability claim and the SS-31 sequence are all community-reported, not trial-derived.
• Start with 250-500 mcg, carry fast carbs around training and glucose-lowering drugs, and skip it if you have MCAS or allergy history, are pregnant or breastfeeding, or are drug-tested.

Check out the pinned Peptide Cheat Sheet for more. 

Not medical advice. Educational only.

Im 15 with open plates 174cm height. I want to increase my height while also not closing my growth plates early. I would like to increase bonemass especially in my face for more definition. Also something that would help me with my skin and Hair. I thought about cycling: cjc 1295 Dac+impamorelin+ghkcu (maybe mk 677).
But in no way am I sure in how to dose it to avoid most risks, not disturbing my normal hormone not to much and maximizing the results.

It would be very nice if you could tell me if my cycle makes sense, which dosage (weekly and per Injection) you would recommend, how to use them, and how to mix them, what side effects there are like hairloss and what kind of price range I should expect for one cycle.
Thank you for your help

follow up to my last post here about batch specific coas. so say i order from peppy care or anyone else and i want the coa for the exact lot im getting. how does that actually work in practice?

do you email them after ordering? ask before? is it a normal request or do they act weird about it?

and the bigger question, if a provider refuses or ghosts the request, is that my answer? because honestly if someone wont show me what lab tested the batch and when, im out. just want to know if thats the standard take or if im being too rigid about it.

i'm trying to get educated here. most coas i see floating around only mention purity, like 99% pure and thats it. but purity of what exactly, and what about the stuff you dont want in there?

should a real coa also cover sterility, endotoxins, identity confirmation? i see heavy metals mentioned sometimes but not consistently.

asking because peppy care advertises batch specific coas and i want to know what a legit one actually looks like before i judge whether theirs means anything. if anyone has an example of what a thorough one covers that would help a lot.

Eloralintide is the amylin compound getting the most attention right now, and the data has moved quickly. Eli Lilly is developing it (LY3841136) as a long-acting, selective amylin receptor agonist for obesity, dosed once weekly. It works through amylin signaling and skips GLP-1 and GIP receptors entirely, which is why it keeps coming up.

What amylin does

Amylin is a hormone released alongside insulin after you eat. It slows gastric emptying, blunts glucagon, and promotes satiety. Eloralintide is built to hit that pathway for a long time. Its half-life in the single-dose study was about 13 to 15 days.

Phase 1

The 12-week multiple-dose study in adults with overweight or obesity found dose-dependent weight loss. Average reduction at week 12 ran from 2.6% to 11.3% across dose groups. The most common adverse events were decreased appetite, headache, and fatigue, mostly mild. Twelve weeks is too short to say anything about long-term results, but it was enough of a signal to keep going.

Phase 2

The 48-week Phase 2 trial in adults without type 2 diabetes reported weight loss of up to 20.1% at the top dose. That's the number that pushed Lilly into Phase 3. The Phase 3 program, called ENLIGHTEN, includes obesity as well as sleep apnea and knee osteoarthritis pain.

The tirzepatide combination

On September 30, Lilly reported 48-week Phase 2b results for eloralintide plus tirzepatide, which they call EloraTZP. It enrolled 367 adults with obesity or overweight and type 2 diabetes. The top combination, eloralintide 9 mg plus tirzepatide 15 mg, averaged 23.3% weight loss and a 2.9% drop in A1C. Tirzepatide 15 mg alone averaged 14.8% and 2.4%. Eloralintide alone ranged from 8.2% to 12.3%.

There's a cost. Across the combination arms, 10.8% to 27% of participants stopped treatment over adverse events, compared with 2.9% on tirzepatide alone. In the trial, the two drugs were separate injections, and Lilly plans Phase 3 with a co-formulation and a gentler escalation schedule.

I'd be careful about comparing that 23.3% to retatrutide. Different populations, different durations, and no head-to-head trial exists.

Why it's worth watching

Amylin gives researchers a way to work on appetite without leaning on the GLP-1 receptor. The question now is how much it adds on top of incretins and what the tolerability looks like once the dose goes up.

Eloralintide is investigational and not approved anywhere.

TL;DR

• Eloralintide is a once-weekly, selective amylin receptor agonist from Eli Lilly with a half-life of roughly two weeks.
• Phase 1 showed 2.6% to 11.3% weight loss at 12 weeks, and Phase 2 showed up to 20.1% at 48 weeks.
• It's in Phase 3 (ENLIGHTEN), including sleep apnea and knee osteoarthritis trials.
• EloraTZP, eloralintide plus tirzepatide, hit 23.3% weight loss at 48 weeks versus 14.8% for tirzepatide alone, with more treatment discontinuations.
• It's investigational, so everything here is trial data and nothing is established practice.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.